Geode Capital Management
SYRE icon

Geode Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Geode Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86.8M Buy
1,720,912
+61,772
+4% +$2.33M 0.01% 1177
2025
Q4 		$54.4M Buy
1,659,140
+433,987
+35% +$11.3M ﹤0.01% 1428
2025
Q3 		$20.5M Sell
1,225,153
-2,079
-0.2% -$33.9K ﹤0.01% 1988
2025
Q2 		$18.4M Buy
1,227,232
+167,669
+16% +$2.48M ﹤0.01% 2000
2025
Q1 		$17.1M Buy
1,059,563
+93,434
+10% +$1.94M ﹤0.01% 1976
2024
Q4 		$22.5M Buy
966,129
+75,081
+8% +$2.2M ﹤0.01% 1905
2024
Q3 		$26.2M Buy
891,048
+125,214
+16% +$3.49M ﹤0.01% 1833
2024
Q2 		$18M Buy
765,834
+435,609
+132% +$14.7M ﹤0.01% 1987
2024
Q1 		$12.5M Buy
330,225
+299,899
+989% +$8.69M ﹤0.01% 2191
2023
Q4 		$653K Buy
30,326
+3,526
+13% +$48.6K ﹤0.01% 3516
2023
Q3 		$328K Buy
26,800
+2,782
+12% +$36.8K ﹤0.01% 3777
2023
Q2 		$271K Hold
24,018
– – ﹤0.01% 3907
2023
Q1 		$174K Hold
24,018
– – ﹤0.01% 4119
2022
Q4 		$270K Buy
24,018
+8,257
+52% +$148K ﹤0.01% 3938
2022
Q3 		$207K Hold
15,761
– – ﹤0.01% 4190
2022
Q2 		$199K Sell
15,761
-11,928
-43% -$418K ﹤0.01% 4271
2022
Q1 		$1.59M Buy
27,689
+259
+0.9% +$21.8K ﹤0.01% 3373
2021
Q4 		$3.26M Sell
27,430
-170
-0.6% -$26.8K ﹤0.01% 3129
2021
Q3 		$5.49M Buy
27,600
+491
+2% +$85.9K ﹤0.01% 2854
2021
Q2 		$4.72M Buy
27,109
+794
+3% +$144K ﹤0.01% 2950
2021
Q1 		$5.21M Buy
26,315
+3,634
+16% +$697K ﹤0.01% 2771
2020
Q4 		$4.46M Sell
22,681
-57
-0.3% -$11.8K ﹤0.01% 2662
2020
Q3 		$4.03M Sell
22,738
-568
-2% -$105K ﹤0.01% 2528
2020
Q2 		$5.39M Buy
23,306
+10,543
+83% +$2.01M ﹤0.01% 2302
2020
Q1 		$1.49M Buy
12,763
+236
+2% +$40.1K ﹤0.01% 2828
2019
Q4 		$2.39M Buy
12,527
+28
+0.2% +$5.5K ﹤0.01% 2902
2019
Q3 		$2.4M Buy
12,499
+536
+4% +$104K ﹤0.01% 2829
2019
Q2 		$2.05M Buy
11,963
+2,334
+24% +$403K ﹤0.01% 2937
2019
Q1 		$1.94M Buy
9,629
+3,125
+48% +$651K ﹤0.01% 2875
2018
Q4 		$1.22M Buy
6,504
+333
+5% +$70.6K ﹤0.01% 3023
2018
Q3 		$1.48M Buy
6,171
+275
+5% +$64.2K ﹤0.01% 3047
2018
Q2 		$1.56M Buy
5,896
+4,670
+381% +$1.15M ﹤0.01% 2992
2018
Q1 		$304K Hold
1,226
– – ﹤0.01% 3563
2017
Q4 		$165K Hold
1,226
– – ﹤0.01% 3719
2017
Q3 		$145K Hold
1,226
– – ﹤0.01% 3738
2017
Q2 		$117K Sell
1,226
-100
-8% -$13.8K ﹤0.01% 3810
2017
Q1 		$246K Buy
1,326
+394
+42% +$55.6K ﹤0.01% 3584
2016
Q4 		$101K Buy
932
+163
+21% +$23.8K ﹤0.01% 3793
2016
Q3 		$123K Buy
+769
New +$107K ﹤0.01% 3755

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Geode Capital Management's SYRE Position: Q1 2026 in Review

Geode Capital Management increased its Spyre Therapeutics (SYRE) stake by 3.7% in Q1 2026, buying an estimated $2.33M and bringing the position to 1,720,912 shares worth $86.8M. The position accounts for 0.01% of the portfolio, ranked #1177.

Geode Capital Management first reported a position in SYRE in Q3 2016 and has held it in 39 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Geode Capital Management held 1,720,912 shares of Spyre Therapeutics worth $86.8M as of Q1 2026.
  • Geode Capital Management bought 61,772 Spyre Therapeutics shares in Q1 2026, an estimated $2.33M.
  • Spyre Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q1 2026, its #1177 holding.
  • Geode Capital Management first reported a position in Spyre Therapeutics in Q3 2016 and has held it in 39 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.